Propel Bio Partners Research
Investment Thesis
Propel Bio Partners is a Los Angeles-founded and headquartered venture/incubator hybrid firm, founded in 2022 by Dr. Leen Kawas (former CEO of Athira Pharma, now LeonaBio) and Richard Kayne (founder of Kayne Anderson Capital Advisors). The firm backs companies developing therapies for rare diseases and other high-need conditions with significant unmet needs, concentrating on late-stage assets approaching key clinical and regulatory milestones or already in active development. Propel's core conviction, as articulated by managing general partner Dr. Kawas, is that "in medicine, scientific breakthroughs are no longer enough" — too many promising therapies fail not because the science is flawed but because execution, regulatory navigation, commercialization strategy, and operational discipline fall short. Propel's hybrid model pairs capital with hands-on operational support across clinical strategy, regulatory planning, and commercialization, aiming to reduce execution risk for portfolio companies. The firm also integrates patient voice and real-world disease experience into diligence and clinical/regulatory/commercial planning, asking whether a therapy meaningfully changes how patients live with a disease rather than optimizing purely for abstract biomarkers or trial endpoints.
Stage Focus
Propel's investments span Seed through Series A and into public/post-IPO positions in late-stage biotech companies, reflecting the firm's emphasis on later-stage, de-risked assets nearing regulatory milestones alongside occasional earlier-stage bets tied to its incubator/hands-on model (e.g., Persephone Biosciences seed, Inherent Biosciences Series A).
Check Size
No specific check-size range is publicly disclosed. Propel co-led Persephone Biosciences' $15M seed round (2022) and led Inherent Biosciences' Series A (2022); it also holds a post-IPO equity position in Achieve Life Sciences (NASDAQ: ACHV), a specialty pharmaceutical company advancing cytisinicline for nicotine dependence.
Lead Tendency
Propel has both led and co-led rounds: it led Inherent Biosciences' Series A financing and co-led Persephone Biosciences' $15M seed round alongside First Bight Ventures and others.
Recent Activity
The firm closed a new $100M fund in May 2026 (following an earlier $150M target fund raised around its 2022 launch), continuing to target late-stage biotech assets — both public and privately held — across infectious disease, oncology, and other high-need therapeutic areas, with an emphasis on near-term development milestones. Portfolio company EIT Pharma received FDA acceptance of a New Drug Application for lonafarnib to treat chronic hepatitis D in August 2026, a notable milestone in a disease area with no FDA-approved therapies. Portfolio company Achieve Life Sciences received a Complete Response Letter from the FDA for its cytisinicline NDA in June 2026, following FDA acceptance of that NDA filing in September 2025.
Portfolio Highlights
- Achieve Life Sciences (NASDAQ: ACHV) — late-stage specialty pharmaceutical company developing cytisinicline for smoking/nicotine cessation; Propel holds a post-IPO equity position.
- EIT Pharma — Kirkland, WA-based biotech developing lonafarnib for chronic hepatitis D (NDA under FDA review) and a candidate for acute respiratory infection; frequently cited by Propel as the clearest expression of its hybrid capital-plus-operational-support model.
- Persephone Biosciences — San Diego-based synthetic biology company developing microbiome-based (synbiotic) therapeutics for infant and patient gut health; Propel co-led its $15M seed round; prior collaborations with Ginkgo Bioworks and Janssen.
- Inherent Biosciences — Salt Lake City-based epigenetic diagnostics and therapeutics company (lead product SpermQT for male-fertility testing); Propel led its Series A; the company later partnered with Posterity Health.
- OmniVis — developer of a point-of-care, handheld device for rapid cholera pathogen detection in water/field settings.
Team
- Leen Kawas, PhD — Managing General Partner and co-founder. Former CEO of Athira Pharma (now LeonaBio), which she took public in 2020 (raised over $400M); serves on the boards of Inherent Biosciences and Persephone Biosciences.
- Richard Kayne, MBA — General Partner. Founder and co-chairman of Kayne Anderson Capital Advisors; founder of Kayne Anderson Rudnick.
- Xue Hua, PhD — Managing Partner, based in Seattle; clinical research, clinical operations, and data science background.
- Jim Harding, CPA, CMA — Finance.
- Erik Gonzalez-Leon, PhD — Manager, biomedical engineering translational research and technical/patentability assessment.
- Joyce Jiang, MPH, PhD — Vice President, health economics, market access, business development, and clinical trial design.
- Safiya Alavi — Analyst.
- Armaan Hirani — Data Science Associate.
- Laurie Heilmann — Venture Partner, commercialization and accelerator strategy.
- Extended Medical and Investment Advisory Board includes Ron Farkas MD PhD, Sylvia McBrinn MBA, Mike Gibbs, Ronald Lee Krall MD, Suzanne Hendrix PhD, Richard Sudek PhD, and Carol Criner.
Decision Process
Propel operates as a partnership between managing general partner Dr. Leen Kawas and general partner Richard Kayne, supported by an internal investment team (Xue Hua, Erik Gonzalez-Leon, Joyce Jiang, and analysts) and a broad medical/investment advisory board that provides clinical, regulatory, and commercial diligence input.
Founder Preferences
Propel favors founders and management teams with credible late-stage clinical or regulatory paths, particularly in rare diseases and areas of significant unmet medical need. The firm places heavy weight on execution capability — clinical, regulatory, and commercial rigor — over pure scientific novelty, and looks for teams open to hands-on operational partnership rather than passive capital.
Geographic Focus
Propel is headquartered in Los Angeles, CA, with a portfolio concentrated in the United States (Seattle, San Diego, Salt Lake City, Kirkland WA, and West Lafayette, IN).